Cancer research · 2018

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.

СтатьяПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАПоддержка правительства СШАПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод пока не подготовлен

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wang Sophia S, Carrington Mary, Berndt Sonja I, Slager Susan L, Bracci Paige M, Voutsinas Jenna, Cerhan James R, Smedby Karin E, Hjalgrim Henrik, Vijai Joseph, Morton Lindsay M, Vermeulen Roel, Paltiel Ora, Vajdic Claire M, Linet Martha S, Nieters Alexandra, de Sanjose Silvia, Cozen Wendy, Brown Elizabeth E, Turner Jennifer, Spinelli John J, Zheng Tongzhang, Birmann Brenda M, Flowers Christopher R, Becker Nikolaus, Holly Elizabeth A, Kane Eleanor, Weisenburger Dennis, Maynadie Marc, Cocco Pierluigi, Albanes Demetrius, Weinstein Stephanie J, Teras Lauren R, Diver W Ryan, Lax Stephanie J, Travis Ruth C, Kaaks Rudolph, Riboli Elio, Benavente Yolanda, Brennan Paul, McKay James, Delfau-Larue Marie-Hélène, Link Brian K, Magnani Corrado, Ennas Maria Grazia, Latte Giancarlo, Feldman Andrew L, Doo Nicole Wong, Giles Graham G, Southey Melissa C, Milne Roger L, Offit Kenneth, Musinsky Jacob, Arslan Alan A, Purdue Mark P, Adami Hans-Olov, Melbye Mads, Glimelius Bengt, Conde Lucia, Camp Nicola J, Glenn Martha, Curtin Karen, Clavel Jacqueline, Monnereau Alain, Cox David G, Ghesquières Hervé, Salles Gilles, Bofetta Paulo, Foretova Lenka, Staines Anthony, Davis Scott, Severson Richard K, Lan Qing, Brooks-Wilson Angela, Smith Martyn T, Roman Eve, Kricker Anne, Zhang Yawei, Kraft Peter, Chanock Stephen J, Rothman Nathaniel, Hartge Patricia, Skibola Christine F

Аннотация

A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes.Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086-96. ©2018 AACR.

Предметные рубрики MeSH

Case-Control Studies Female Genetic Heterogeneity Genome-Wide Association Study Heterozygote Histocompatibility Antigens Class I Histocompatibility Antigens Class II Humans Lymphoma, Non-Hodgkin Male Prospective Studies

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.

Ошибки и ограничения

Аннотация

Предметные рубрики MeSH